52nd week of 2008 patent applcation highlights part 52 |
Patent application number | Title | Published |
20080318893 | Blockade of Calcium Channels - Knock-down of L-type calcium channel beta subunit (LTCCβ) attenuates the hypertrophic response both in vitro and in vivo without compromising systolic performance. Knock-down can be accomplished by administration of a vector encoding a short hairpin RNA which specifically modulates expression of LTCCβ. Suppression of the LTCCβ expression represents a therapeutic modality for cardiac hypertrophy. | 2008-12-25 |
20080318894 | RNA ANTAGONIST COMPOUNDS FOR THE MODULATION OF HER3 - The invention relates to oligomer compounds (oligomers), which target HER3 mRNA in a cell, leading to reduced expression of HER3 and/or HER2 and/or EGFR. Reduction of HER3 and/or HER2 and/or EGFR expression is beneficial for a range of medical disorders, such hyperproliferative disorders (e.g., cancer). The invention provides therapeutic compositions comprising oligomers and methods for modulating the expression of HER3 and/or HER2 and/or EGFR using said oligomers, including methods of treatment. | 2008-12-25 |
20080318895 | INTRANASAL DELIVERY OF NUCLEIC ACID MOLECULES - Aerosol delivery of nucleic acids to the lungs using viral vectors, polymers, surfactants, or excipients has been described. Compositions for intranasal administration are described that contain nucleic acids without viral or plasmid vectors and with little to no polymers, surfactants, or excipients. In one embodiment, the composition for intranasal delivery consists essentially of at least one nucleic acid and an aqueous solution. Suitable nucleic acids for intranasal delivery include, but are not limited to, dsDNA, dsRNA, ssDNA, ssRNA, short interfering RNA, micro-RNA, and antisense RNA Methods for treatment, diagnosis, or prevention of at least one symptom or manifestation of a lung disease are also described consisting of administration by intranasal delivery an effective amount of a composition containing a nucleic acid. The composition may be formulated as a liquid or aerosol or other acceptable formulation for intranasal administration. | 2008-12-25 |
20080318896 | Methods and Compositions for Controlling of Efficacy of RNA Silencing - Based at least in part on an understanding of the mechanisms by which small RNAs (e.g., naturally-occurring miRNAs) mediate RNA silencing in plants, rules have been established for determining, for example, the degree of complementarity required between an RNAi-mediating agent and its target, i.e., whether mismatches are tolerated, the number of mismatches tolerated, the effect of the position of the mismatches, etc. Such rules are useful, in particular, in the design of improved RNAi-mediating agents which allow for more exact control of the efficacy of RNA silencing. | 2008-12-25 |
20080318897 | Composition Containing Swelling Agent Composed of Swellable Water-Soluble Polysaccharide, and Food, Anti-Obesity Agent and Constipation Alleviator Each Containing the Composition - A composition containing a swelling agent is provided, which less burdens the stomach and intestine even after excessive intake. A food, anti-obesity agent and constipation alleviator each containing the composition is also provided. | 2008-12-25 |
20080318898 | INCLUSION COMPLEXES OF BUTYLPHTHALIDE WITH CYCLODEXTRIN OR ITS DERIVATIVES, A PROCESS FOR THEIR PREPARATION AND THE USE THEREOF - The present invention relates to the inclusion complexes of butylphthalide, which is D, L-mixed or levorotatory, with cyclodextrin or cyclodextrin derivatives, to a process for their preparation and the use thereof. In the invention, the butylphthalide is complexed with cyclodextrin or cyclodextrin derivatives, preferably with hydroxypropyl-β-cyclodextrin in order to increase the water-solubility of butylphthalide, develop clinical solid or liquid formulations and improve the therapeutic effect of butylphthalide. The inclusion complex, in which the molar ratio of butylphthalide to cyclodextrin or cyclodextrin derivatives is in the range of 1:1-10, can be used to prepare infusion, injection, injectable powder, liquids for oral administration, syrup, tablets, granules, dispersible tablets and others. | 2008-12-25 |
20080318899 | Pyridazine Compounds, Compositions and Methods - The invention relates to novel chemical compounds and methods of making and using the same. In particular, the invention provides pyridazine compounds and/or related heterocyclic derivatives, compositions comprising the same, and methods of using pyridazine compounds and/or related heterocyclic derivatives and compositions comprising the same, for modulation of cellular pathways (e.g., signal transduction pathways), for treatment or prevention of inflammatory diseases (e.g., Alzheimer's disease), for research, drug screening, and therapeutic applications. | 2008-12-25 |
20080318900 | Cosmetic Compositions Comprising At Least One Bis-Urea Derivative - Disclosed herein is a cosmetic composition comprising at least one continuous liquid fatty phase, comprising at least one compound of formula (I), or a salt and/or isomer thereof: | 2008-12-25 |
20080318901 | Novel Lysophosphatidic Acid Receptor Selective Antagonists - The present invention is directed to compositions comprising lysophosphatidic acid analogs and methods of using such analogs as agonist or antagonists of LPA receptor activity. In addition the invention is directed to LPA receptor agonists that vary in the degree of selectivity at individual LPA receptors (i.e. LPA1, LPA2 and LPA3). More particularly the present invention is directed to LPA analogs wherein the glycerol is replaced with ethanolamine and a variety of substitutions have been linked at the second carbon atom. | 2008-12-25 |
20080318902 | TRIHETEROCYCLIC COMPOUNDS AND COMPOSITIONS THEREOF - The present invention relates to novel Triheterocyclic Compounds, compositions comprising a Triheterocyclic Compound, and methods useful for treating or preventing cancer or a neoplastic disorder comprising administering a Triheterocyclic Compound. The compounds, compositions, and methods of the invention are also useful for inhibiting the growth of a cancer cell or neoplastic cell, treating or preventing a viral infection, or inhibiting the replication and/or infectivity of a virus. | 2008-12-25 |
20080318903 | METHODS FOR TREATING CANCER - The present invention relates to novel Triheterocyclic Compounds, compositions comprising a Triheterocyclic Compound, and methods useful for treating or preventing cancer or a neoplastic disorder comprising administering a Triheterocyclic Compound. The compounds, compositions, and methods of the invention are also useful for inhibiting the growth of a cancer cell or neoplastic cell, treating or preventing a viral infection, or inhibiting the replication and/or infectivity of a virus. | 2008-12-25 |
20080318904 | DEUTERIUM-ENRICHED TENOFOVIR - The present application describes deuterium-enriched tenofovir, pharmaceutically acceptable salt forms thereof, and methods of treating using the same. | 2008-12-25 |
20080318905 | Prodrugs and methods of making and using the same - Prodrugs of parent drugs and methods of making and using the same are described. The prodrugs comprise an amine-containing parent drug moiety and a prodrug moiety, such as methoxyphosphonic acid or ethoxyphosphonic acid. The prodrugs may be employed in therapy for the treatment of various indications, such as pain, and in methods of decreasing the abuse potential of abuse-prone drugs and/or delaying the onset of parent drug activity and/or prolonging parent drug activity as compared to administration of a parent drug. | 2008-12-25 |
20080318906 | BISPHOSPHONATE COMPOUNDS AND METHODS FOR BONE RESORPTION DISEASES, CANCER, BONE PAIN, IMMUNE DISORDERS, AND INFECTIOUS DISEASES - Bisphosphonate compounds and related methods of making and using are disclosed, including pyridinium-1-yl, quinolinium-1-yl, and related compounds. The activity of compounds is disclosed in the context of functional assays such as | 2008-12-25 |
20080318907 | Nitroxide Free Radical Synergized Antineoplastic Agents - Nitroxide free radicals attached to antineoplastic agents can synergize their potencies to cancer cells. This invention relates to any antineoplastic agents and their derivatives chemically attached with nitroxide free radicals, such as TEMPO and its radical derivatives. This invention also relates to precursors of such compounds, as well as the products formed from the adducts after administration. | 2008-12-25 |
20080318908 | USE OF GABA AND GABAB AGONISTS - The present invention provides methods of stimulating tissue growth, including islet cell growth, by administering GABA or a GABA agonist to act on GABA | 2008-12-25 |
20080318909 | Use Of Linoleic Compounds Against Heart Failure - Linoleic acid and related cardiolipin products are used as dietary supplements that provide cardiac benefits against a variety of cardiac related symptoms and diseases. For example, the disclosed compositions and methods may be used to treat or prevent hypertension, ischemic cardiomyopathy, heart disease, Barth Syndrome and heart failure. | 2008-12-25 |
20080318910 | Controlled-Release Oral Dosage Form - A controlled-release oral dosage form suitable for administration to a mammal. The dosage form comprises a drug and an organic acid or a salt thereof. The dosage form releases no more than 60% the total amount of the drug within about a first hour, the remaining amount of the drug being released over a period of time of about 5 to about 8 hours subsequent to the first hour. Such a dosage form can be particularly useful for delivery of various pH-dependent solubility drugs. | 2008-12-25 |
20080318911 | 20-Cyclopropyl, 26,27-Alkyl/Haloalkyl Vitamin D3 Compounds and Methods of Use Thereof - The invention provides vitamin D | 2008-12-25 |
20080318912 | Medicaments for Treating Chronic Respiratory Disease - There is provided the use of a methylxanthine compound and a steroid in a synergistic combination for the treatment of a respiratory disease, wherein the methylxanthine compound is administered at a dose, which, in isolation, is not effective to treat said disease. | 2008-12-25 |
20080318913 | Combination of Methylxanthine Compounds and Steroids to Treat Chronic Respiratory Diseases - There is provided the use of a methylxanthine derivative such as theophylline and a steroid in a synergistic combination for the treatment of chronic obstructive pulmonary disease, wherein the combination is administered by the inhaled route for pulmonary delivery. | 2008-12-25 |
20080318914 | METHODS FOR THE TREATMENT OF A TRAUMATIC CENTRAL NERVOUS SYSTEM INJURY - Methods of treating a subject with a traumatic central nervous system injury, more particularly, a traumatic brain injury, are provided. The methods comprise a therapy comprising a constant or a two-level dosing regime of progesterone. In one method, a subject in need thereof is administered at least one cycle of therapy, wherein the cycle of therapy comprises administering a therapeutically effective two-level intravenous dosing regime of progesterone. The two-level dosing regime comprises a first time period, wherein a higher hourly dose of progesterone is administered to the subject, followed by a second time period, wherein a lower hourly dose of progesterone is administered to the subject. | 2008-12-25 |
20080318915 | DEUTERIUM-ENRICHED FLUTICASONE PROPIONATE - The present application describes deuterium-enriched fluticasone propionate, pharmaceutically acceptable salt forms thereof, and methods of treating using the same. | 2008-12-25 |
20080318916 | Novel alpha glucosidase inhibitors from lichens - This invention is directed to a novel method for the inhibition of α-glucosidase enzyme and thus treating diabetes, viral infections, fungal infections, autoimmune function disorders and obesity using compounds derived as lichen metabolites; more specifically, this includes the therapeutic applications of methylorsellinate (2,4-dihydroxy-6-methylbenzoate, Compound I), methyl-β-orinolcarboxylate (2,4-dihydroxy-3,6-dimethylbenzoate, Compound II) and zeorin (6,22-hopanediol, Compound III). | 2008-12-25 |
20080318917 | POLYETHYLENE GLYCOLATED SUPEROXIDE DISMUTASE MIMETICS - Compounds and methods for utilizing compounds comprising a superoxide dismutase mimetic covalently linked to polyethylene glycol. Methods are also provided for preparing a superoxide dismutase mimetic covalently linked to a polyethylene glycol, the methods comprising reacting an activated polyethylene glycol with a superoxide, dismutase mimetic, or alternatively, reacting a superoxide dismutase mimetic with an activated polyethylene glycol. A method is also provided for preventing or treating a disease or disorder in which superoxide anions are implicated, comprising administering to a subject in need thereof, a therapeutically effective amount of a compound comprising a superoxide dismutase mimetic covalently linked to a polyethylene glycol. Methods of determining the safety and efficacy of the compounds ere also provided. Methods for determining the safety and efficacy can include methods in lab animals and humans. | 2008-12-25 |
20080318918 | Methods for Treatment and Prevention of Otitis Media Using Nonionic Surfactants to Facilitate Transmembrane Drug Delivery into the Middle Ear - Methods for treating and preventing middle ear infections by transmembrane administration of medicament-containing transmembrane carrier compositions comprising a nonionic polymer surfactant, such as an alkyl aryl polyether alcohol (e.g., tyloxapol) to the tympanic membrane. The medicaments delivered according to the methods of the invention include antibiotic, antiviral, anti-fungal and anti-inflammatory agents that are useful in treatment and/or prophylaxis of middle ear infections and their sequelae. | 2008-12-25 |
20080318919 | Cefquinome Compositions and Methods of Their Use - This invention is directed generally to cefquinome compositions, processes for making such compositions, uses of such compositions to make medicaments, kits for making such compositions, and methods for using such compositions and kits to treat infections. | 2008-12-25 |
20080318920 | DEUTERIUM-ENRICHED EZETIMIBE - The present application describes deuterium-enriched ezetimibe, pharmaceutically acceptable salt forms thereof, and methods of treating using the same. | 2008-12-25 |
20080318921 | Tricyclic 6-Alkylidene-Penems as Beta-Lactamase Inhibitors - The present invention provides a compound of formula I, pharmaceutical compositions and the use thereof for the treatment of bacterial infection or disease in a patient in need thereof. | 2008-12-25 |
20080318922 | Bicyclic Pyrrole Derivatives - Compounds represented by the general formula (I), prodrugs thereof, or pharmaceutically acceptable salts of both are provided as compounds which have high DPP-IV inhibiting activity and are improved in safety, toxicity and so on: (I) | 2008-12-25 |
20080318923 | 1,3-Dihydro-2H-Indole-2-One Compound and Pyrrolidine-2-One Compound Fused With Aromatic Heterocycle - It is intended to provide a drug which is efficacious against pathological conditions relating to arginine-vasopressin V1b receptor. More particularly speaking, it is intended to provide a drug which has a therapeutic or preventive effect on depression, anxiety, Alzheimer's disease, Parkinson's disease, Huntington's chorea, eating disorders, hypertension, digestive diseases, drug addiction, epilepsy, brain infarction, brain ischemia, brain edema, head injury, inflammation, immune diseases, alopecia and so on. As the results of intensive studies, a novel 1,3-dihydro-2H-indol-2-one compound and a pyrrolidin-2-one compound fused with a heteroaromatic ring, which are highly selective antagonists of arginine-vasopressin V1b receptor, have high metabolic stabilities and show favorable brain penetration and high plasma concentrations, are found, thereby achieving the above objective. | 2008-12-25 |
20080318924 | PHENOXYPYRIDINE DERIVATIVE SALTS AND CRYSTALS THEREOF, AND PROCESS FOR PREPARING THE SAME - The invention provides acid addition salts of the compounds represented by formula (1) or (2), or crystals thereof, and processes for preparing the same. The salts or crystals have HGFR inhibitory activity and excellent physical properties (solubility, safety, etc.) and are therefore useful as anti-tumor agents, angiogenesis inhibitors and inhibitors for metastasis for a various types of tumor. | 2008-12-25 |
20080318925 | Compounds and Uses Thereof - 849 - This invention relates to the use of compounds having the structural formula I below: | 2008-12-25 |
20080318926 | Methods of Treating Mood Disorders Using Pyridyloxymethyl and Benzisoxazole Azabicyclic Derivatives - An aminomethylpyridyloxymethyl/benzisoxazole substituted azabicyclic compound, a pharmaceutical composition comprising same, and a method of treating a mood disorder selected from the group consisting of Somatization Disorder, Borderline Personality Disorder, Narcissistic Personality Disorder, Suicidal Ideation, and Antisocial Personality Disorder. | 2008-12-25 |
20080318927 | Substituted monocyclic CGRP receptor antagonists - Compounds of formula I: | 2008-12-25 |
20080318928 | BENGAMIDES WITH A SUBSTITUTED CAPROLACTAM CYCLE, METHOD FOR THE PREPARATION THEREOF, COMPOSITIONS CONTAINING THEM AND USE THEREOF - The invention relates to the preparation of substituted caprolactams, a method for the preparation thereof, compositions containing them and the use thereof as a medicament, particularly as anticancer agents. | 2008-12-25 |
20080318929 | Pyrimidine Derivatives Useful as Inhibitors of Pkc-Theta - Disclosed are novel compounds of formula (I) wherein R | 2008-12-25 |
20080318930 | Sulfonyl Compound as Inhibitors of 11-Beta-Hydroxysteroid Dehydrogenase-1 - Sulfonyl derivatives of structural formula I are selective inhibitors of the 11β-hydroxysteroid dehydrogenase-1. The compounds are useful for the treatment of diabetes, such as noninsulin-dependent diabetes (NIDDM), hyperglycemia, obesity, insulin resistance, dyslipidemia, hyperlipidemia, hypertension, Metabolic Syndrome or Syndrome X, and other symptoms associated with NIDDM. | 2008-12-25 |
20080318931 | Treatment of Disorders and Diseases of the Colon - A method and a composition for the treatment of an Inflammatory Bowel Disease (IBD) or intestine polyposes is described. The method includes the local administration to the colon of a therapeutically effective amount of at least one Selective Serotonin Reuptake Inhibitor (SSRI) or at least one tricyclic antidepressant (TCA). | 2008-12-25 |
20080318932 | Sodium Channel Blocker Compositions and the Use Thereof - Methods of treating or preventing chronic pain or convulsion are disclosed by administering to an animal a sodium channel blocker and at least one of gabapentin and pregabalin. Also disclosed are pharmaceutical compositions and kits for the treatment or prevention of chronic pain or convulsion. | 2008-12-25 |
20080318933 | 5-Sulfonyl-1-Piperidinyl Substituted Indole Derivatives as 5-Ht6 Receptor Antagonists for the Treatment of Cns Disorders - The present invention relates to novel indole derivatives such as compounds of the formula (I): | 2008-12-25 |
20080318934 | Diazepinoes - The invention relates to compounds of the formula (I), to the preparation and use thereof for the preparation of a medicament for the treatment of diseases, in particular tumours and/or diseases in the development or course of which kinases are involved. | 2008-12-25 |
20080318935 | SUBSTITUTED IMIDAZOHETEROCYCLES - The present invention provides substituted imidazoheterocyclic compounds having the structure of formula I | 2008-12-25 |
20080318936 | Substituted 5-Phenyl-3,6-Dihydro-2-Oxo-6H-1,3,4-Thiadiazines -
Compounds of the formula (I), in which R | 2008-12-25 |
20080318938 | METHODS FOR TREATING ABERRANT CELL PROLIFERATION DISORDERS - The invention relates in part to methods for inhibiting proliferation of cancer cells and treating one or more cell proliferative conditions using compounds described herein. | 2008-12-25 |
20080318939 | METHODS FOR TREATING OPHTHALMIC DISORDERS - The invention relates in part to methods for treating ophthalmic conditions using compounds described herein. The conditions to be treated include various ocular cancers. The compositions employed include a polycyclic quinolinone derivative or related heteroaromatic analog thereof. | 2008-12-25 |
20080318940 | Quinazolinone Derivatives as Vanilloid Antagonists - The invention relates to quinazolinone compounds of the formula | 2008-12-25 |
20080318941 | 4' SUBSTITUTED COMPOUNDS HAVING 5-HT6 RECEPTOR AFFINITY - The present disclosure provides compounds having affinity for the 5-HT | 2008-12-25 |
20080318942 | Fredericamycin Derivatives - The invention relates to new fredericamycin derivatives, to pharmaceutical drugs containing them or their salts, and to the use of the fredericamycin derivatives for the treatment of diseases, especially tumor diseases. | 2008-12-25 |
20080318943 | Compounds and Uses Thereof - 848 - This invention relates to novel compounds having the structural formula I below: | 2008-12-25 |
20080318944 | N-AROYL CYCLIC AMINE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS - Disclosed are N-aroyl cyclic amine derivatives having the formula: | 2008-12-25 |
20080318945 | Novel Compounds - This invention relates to novel compounds useful in the treatment of diseases associated with TRPV4 channel receptor. More specifically, this invention relates to certain substituted piperazines, according to Formula I | 2008-12-25 |
20080318946 | Di-amino-substituted heterocyclic compounds and methods of use - The present invention comprises a new class of compounds capable of modulating the c-kit receptor and, accordingly, useful for treatment of c-kit mediated diseases, including various fibrotic and mast cell related diseases such as mastocytosis. The compounds have a general Formula I | 2008-12-25 |
20080318947 | Inhibitors of Akt Activity - Invented are novel 1H-imidazo[4,5-c]pyridin-2-yl compounds, the use of such compounds as inhibitors of protein kinase B activity and in the treatment of cancer and arthritis. | 2008-12-25 |
20080318948 | Organic Compounds - The present invention provides compounds of the formula | 2008-12-25 |
20080318949 | Pyrazolopyrimidinone Derivatives, Their Preparation And Their Use - The invention discloses a series of pyrazolopyrimidinone derivatives, which have the following chemical structure, their preparation methods and use, | 2008-12-25 |
20080318950 | Quinazoline Derivatives as a Multiplex Inhibitor and Method For the Preparation Thereof - The present invention relates to a novel quinazoline derivative and a pharmaceutically acceptable salt thereof as a multiplex inhibitor, a method for the preparation thereof, and a pharmaceutical composition and a therapeutic composition comprising same as an active ingredient. The inventive quinazoline derivative as a multiplex inhibitor can selectively and effectively inhibit diseases caused by the overactivity of a tyrosine kinase. | 2008-12-25 |
20080318951 | Dual-acting benzoimidazole antihypertensive agents - The invention is directed to compounds having the formula: | 2008-12-25 |
20080318952 | DIARYL-SUBSTITUTED TETRAHYDROISOQUINOLINES AS HISTAMINE H3 RECEPTOR AND SEROTONIN TRANSPORTER MODULATORS - Certain diaryl-substituted tetrahydroisoquinoline compounds are histamine H | 2008-12-25 |
20080318953 | Substituted Pyridine Derivatives - The present invention relates to pyridine derivatives of the general formula (I) and their use as openers of the KCNQ family potassium ion channels for the treatment of CNS disorders. | 2008-12-25 |
20080318954 | Compounds - The present invention relates to compounds of formula (I), or a pharmaceutically acceptable salts thereof, wherein: Z | 2008-12-25 |
20080318955 | Novel Thiophene Derivatives as Sphingosine-1-Phosphate-1 Receptor Agonists - The invention relates to novel thiophene derivatives, their preparation and their use as pharmaceutically active compounds. Said compounds particularly act as immunosuppressive agents. | 2008-12-25 |
20080318956 | INFLAMMATORY CYTOKINE RELEASE INHIBITOR - A medicament having inhibitory activity against NF-κB activation, which comprises a compound represented by the following general formula (I) or a pharmacologically acceptable salt as an active ingredient: | 2008-12-25 |
20080318957 | POLYBASIC BACTERIAL EFFLUX PUMP INHIBITORS AND THERAPEUTIC USES THEREOF - Disclosed are compounds having polybasic functionalities. The compounds inhibit bacterial efflux pump inhibitors and are used in combination with an anti-bacterial agent to treat or prevent bacterial infections. These combinations can be effective against bacterial infections that have developed resistance to anti-bacterial agents through an efflux pump mechanism. | 2008-12-25 |
20080318958 | New utilities of tricyclic compounds - Pharmaceutical compositions for enhancing the expression of apoAI are provided, which are used as medicaments for treatment of cardiovascular diseases on the basis of improving the functions of HDL. | 2008-12-25 |
20080318959 | Compounds that Inhibit Hiv Particle Formation - The present invention describes novel methods of identifying compounds which inhibit HIV particle formation and Rev-dependent HIV production. The present invention also provides methods and compounds for inhibiting HIV particle formation and or treating patients infected with HIV. | 2008-12-25 |
20080318960 | PAR2-modulating compounds and their use - The present invention relates to compounds, and uses thereof, having the chemical formula: | 2008-12-25 |
20080318961 | Drugs comprising chymase inhibitors and ACE inhibitors as effective ingredients - It is an object of the present invention to provide drugs which are effective for treatment of hypertension, cardiac disease (cardiac hypertrophy, cardiac failure, myocardial infarction, etc.), cerebral apoplexy, nephritis and the like. The invention also provides circulatory disease treatment agents in forms that allow combined use of chymase inhibitors and ACE inhibitors, and circulatory disease treatment methods which produce simultaneous chymase inhibition and ACE inhibition. | 2008-12-25 |
20080318962 | Fungicides Based on Nitrogen-Containing Heterocycles - The compound of the general formula (I), wherein W, X, Y, Z, R, R | 2008-12-25 |
20080318963 | 1-[6,7-Substituted Alkoxyquinoxalinyl) Aminocarbonyl]-4-(Hetero) Arylpiperazine Derivatives - The present invention relates to novel quinoxaline-piperazine compounds, 1-[(6,7-substituted alkoxyquinoxalinyl)aminocarbonyl]-4-(hetero)arylpiperazine derivatives and their pharmaceutically acceptable salts, a process for their preparation thereof, and compositions containing such compounds. Therapeutic methods for the treatment of hyperproliferative disorders, including cancers, by administering quinoxalin-piperazine compounds are also included. | 2008-12-25 |
20080318964 | DEUTERIUM-ENRICHED ESZOPICLONE - The present application describes deuterium-enriched eszopiclone, pharmaceutically acceptable salt forms thereof, and methods of treating using the same. | 2008-12-25 |
20080318965 | Derivatives of Alpha2-Adrenergic Receptor Agonist - The present invention relates to alpha | 2008-12-25 |
20080318966 | Sinomenine Derivatives and Preparation and Uses Thereof - The present invention relates to the preparation and pharmacological use of sinomenine derivatives of formula I. The approach disclosed herein is the modification of D ring by-substituting for R. Additional substitutions in the other rings are also provided herein. Several of the sinomenine derivatives have significantly greater anti-inflammation activity when compared with the parent compound. | 2008-12-25 |
20080318967 | Hair Growth Promoting Agents - The present invention is directed to crystalline forms of 6-[[(3S,4R)-3,4-dihydro-3-hydroxy-6-[(3-hydroxyphenyl)sulfonyl]-2,2,3-trimethyl-2H-1-benzopyran-4-yl]oxy]-2-methyl-3(2H)-pyridazinone, formulations containing at least one of these crystalline forms and their use to promote hair growth. | 2008-12-25 |
20080318968 | Chemical Compounds - The invention relates to a novel group of compounds of Formula (I) or a salt thereof: | 2008-12-25 |
20080318969 | Anti-anginal compounds - This invention relates to novel compounds that partially inhibit fatty acid oxidation and pharmaceutically acceptable salts thereof. More specifically, this invention relates to novel compounds that are derivatives of ranolazine. This invention also provides compositions comprising one or more compound of this invention and a carrier and the use of the disclosed compounds and compositions in methods of treating diseases and conditions that are beneficially treated by partial fatty acid oxidation inhibitors, such as ranolazine. | 2008-12-25 |
20080318970 | Treatment of Infectious Diseases - The present invention is directed to the use of chemosensitising compounds, in particular thioxanthene derivatives and phenothiazine derivatives, for treatment of infectious diseases in combination with an anti-infective agent. The invention furthermore relates to compositions comprising said chemosensitising compounds and anti-infective agents. | 2008-12-25 |
20080318971 | TREATMENT OF IMATINIB RESISTANT LEUKEMIA - The present invention provides 4-anilino-3-quinolinecarbonitriles compounds useful for treating a subject having an BcrAbl positive leukemia that is resistant to imatinib. | 2008-12-25 |
20080318972 | 5-HT1A RECEPTOR SUBTYPE AGONIST - The present invention relates to a method of treating a patient suffering from a disorder of the central nervous system associated with 5-HT | 2008-12-25 |
20080318973 | Urotensin II receptor antagonists - This invention is directed to a compound of Formula (I): | 2008-12-25 |
20080318974 | Compounds Useful for Inhibiting Chk1 - Aryl- and heteroaryl-substituted urea compounds useful in the treatment of diseases and conditions related to DNA damage or lesions in DNA replication are disclosed. Methods of making the compounds, and their use as therapeutic agents, for example, in treating cancer and other diseases characterized by defects in DNA replication, chromosome segregation, or cell division also are disclosed. | 2008-12-25 |
20080318975 | Indolylmaleimide Derivatives - A compound of formula (I) | 2008-12-25 |
20080318976 | Alpha-Hydroxy Amides as Bradykinin Antagonists or Inverse Agonists - α-Hydroxy amide derivatives of the general formula (I) are bradykinin B1 antagonists or inverse agonists useful in the treatment or prevention of symptoms such as pain and inflammation associated with the bradykinin B1 pathway. R | 2008-12-25 |
20080318977 | Condensed Pyridines as Kinase Inhibitors - New compounds of formula (I), wherein the meanings for the various substituents are as disclosed in the description. These compounds are useful as p38 kinase inhibitors. | 2008-12-25 |
20080318978 | HETEROCYCLIC COMPOUNDS AND THEIR USE AS ALDOSTERONE SYNTHASE INHIBITORS - The application relates to novel heterocyclic compounds of the general formula (I) in which R, R | 2008-12-25 |
20080318979 | DERIVATIVES OF 4-(N-AZACYCLOALKYL) ANILIDES AS POTASSIUM CHANNEL MODULATORS - This invention provides potassium channel modulators which are compounds of formula I | 2008-12-25 |
20080318980 | USE OF 7-(PYRIMIDIN-4 YL)-IMIDAZO[1,2-a]PYRIMIDIN-5(1H)-ONES AS GSK-3BETA INHIBITORS - The invention relates to a imidazo[1,2-a]pyrimidone derivative represented by formula (I) or a salt thereof: | 2008-12-25 |
20080318981 | Novel Compounds 480 - There are disclosed novel 5,7-disubstituted [1,3]thiazolo[4,5-d]pyrimidin-2(3H)-one derivatives of formula (I) | 2008-12-25 |
20080318982 | Pharmaceutical Combination for the Treatment of Luts - This invention relates to the combined use of a PDE5 inhibitor and a muscarinic antagonist in the treatment of lower urinary tract symptoms (LUTS), such as urgency, frequency, nocturia and urge incontinence. | 2008-12-25 |
20080318983 | A2B ADENOSINE RECEPTOR ANTAGONISTS - Disclosed are methods for treating asthma, inflammatory gastrointestinal tract disorders, cancer, cardiovascular diseases, neurological disorders, and diseases related to undesirable angiogenesis using A | 2008-12-25 |
20080318984 | Compounds Having Activity in Correcting Mutant-Cftr Processing and Uses Thereof - The invention provides compositions, pharmaceutical preparations and methods for correcting cellular processing (e.g., folding, trafficking, or post-translational modification) of a mutant-cystic fibrosis transmembrane conductance regulator protein (e.g., ΔF508 CFTR) that are useful for the treatment of cystic fibrosis (CF). The compositions and pharmaceutical preparations of the invention may comprise one or more aminobenzothiazole-containing compounds, aminoarylthiazole-containing compounds, quinazolinylaminopyrimidinone-containing compounds, bisaminomethylbithiazole-containing compounds, or phenylaminoquino-line-containing compounds of the invention, or an analog or derivative thereof. | 2008-12-25 |
20080318985 | Novel 2-Aminopyrimidinone Or 2-Aminopyridinone Derivatives and Their Use -
This invention relates to novel compounds having the structural formula Ia or Ib below: (Ia); (Ib) and to their pharmaceutically acceptable salts, compositions and methods of use. These novel compounds provide a treatment or prophylaxis of cognitive impairment, Alzheimer Disease, neurodegeneration and dementia. | 2008-12-25 |
20080318986 | Ddc Compositions - A composition comprising from 1% to 3% dDC which is aqueous and ophthalmically acceptable is disclosed herein. | 2008-12-25 |
20080318987 | METHODS FOR MODULATING BONE FORMATION AND MINERALIZATION - Methods and compositions for modulating bone formation and mineralization are described. | 2008-12-25 |
20080318988 | Pyrimidylaminobenzamide Derivatives For the Treatment of Neurofibromatosis - The present invention relates to the use of pyrimidylaminobenzamide derivatives for the preparation of a drug for the treatment of non-cancerous, benign brain tumors, especially for the curative and/or prophylactic treatment of NF, and to a method of treating non-cancerous, benign brain tumors, especially for the curative and/or prophylactic treatment of NF. | 2008-12-25 |
20080318989 | Pyrimidine Kinase Inhibitors - The invention provides novel kinase inhibitors that are useful as therapeutic agents for example in the treatment malignancies where the compounds have the general formula (I) wherein ring A, X, Y, Z, R | 2008-12-25 |
20080318990 | SPIROINDOLINES AS MODULATORS OF CHEMOKINE RECEPTORS - The present invention relates to a compound of the following formula: | 2008-12-25 |
20080318991 | SPIROCYCLES AS INHIBITORS OF 11-BETA HYDROXYL STEROID DEHYDROGENASE TYPE 1 - The present invention relates to certain spirocyclic compounds that are inhibitors of 11-β hydroxyl steroid dehydrogenase type 1 (11βHSD1), compositions containing the same, and methods of using the same for the treatment of diabetes, obesity and other diseases. | 2008-12-25 |
20080318992 | METHOD OF USING A PKC INHIBITOR TO REVERSE PREFRONTAL CORTICAL DECLINES - Aging is associated with deficiencies in the prefrontal cortex, including working memory impairment, and compromised integrity of neuronal dendrites. The role of Protein Kinase C(PKC) in age-related prefrontal cortical impairments had not been previously determined. The inventors provides evidence that PKC activity is associated with prefrontal cortical dysfunction in aging. The inventors provide methods of reversing the effects of prefrontal cortical decline, improving cognition, and improving working memory in aged subjects by providing a phenanthridinium alkaloid or closely related compound to the subject. The inventors found chelerythrine reversed working memory impairments in aged rats and enhanced working memory in aged rhesus monkeys. Improvement correlated with age, with older monkeys demonstrating a greater degree of improvement following PKC inhibition. The inventors findings indicate that PKC is dysregulated in aged subjects and that PKC inhibitors may be used to treatment improve cognition in the elderly. | 2008-12-25 |
20080318993 | Method of Treating Pain Utilizing Controlled Release Oxymorphone Pharmaceutical Compositions and Instruction on Dosing for Hepatic Impairment - The invention pertains to a method of using oxymorphone in the treatment of pain by providing a patient with an oxymorphone dosage form and informing the patient or prescribing physician that the bioavailability of oxymorphone may be increased in patients with hepatic impairment. | 2008-12-25 |